While not a substitute for randomized trials, indirect cross-trial comparisons serve a crucial clinical function. They provide data-driven talking points to help patients make informed decisions based on personal priorities, such as maximizing remission duration, when direct comparative evidence does not exist.
The CLL17 study revealed a significant difference in undetectable Minimal Residual Disease (UMRD) rates between treatment arms, yet Progression-Free Survival (PFS) curves were not statistically different. This challenges the assumption that UMRD can consistently serve as a direct proxy for long-term survival outcomes in all contexts.
Regimens like acalabrutinib plus venetoclax allow clinicians to start one drug and add the second months later. This flexibility accommodates patients' personal schedules, such as planned travel, making treatment initiation easier and improving the patient experience without compromising the regimen's core structure.
An MD Anderson study suggests adding obinutuzumab later in treatment only for patients failing to achieve undetectable MRD, rather than upfront for all. This "delayed add-on" strategy improves the safety profile by reducing rates of severe infection and neutropenia while reserving the potent antibody for patients who need it most.
The SEQUOIA study showed that for high-risk CLL patients (e.g., p53 mutated), extending treatment with zanubrutinib and venetoclax beyond the planned duration significantly increases rates of undetectable MRD. This suggests a personalized, response-adapted approach, challenging the rigid concept of "fixed-duration" for all.